Folate form gains FDA NDI approval

By Shane Starling

- Last updated on GMT

Related tags: Folic acid, Nutrition

Italian supplier Gnosis Bioresearch has won New Dietary Ingredient (NDI) approval from the Food and Drug Administration for a synthetic folate salt form.

The ingredient, called Quatrefolic, is used to tackle stability and solubility issues that can occur with some forms of calcium salts.

Gnosis marketing manager Lorena Carboni said the NDI notification adds to GRAS status the ingredient already enjoys for use in the US food supply.

The company’s offering is a form of 5-methylfolate calcium salt which it derives from vegetarian-sourced glucosamine.

“Irrespective of whether ingested food contains natural or synthetically-derived folates, these are metabolized to 5-methyltetrahydrofolate, which is considered the biologically active form of the B-vitamin folic acid,”​ the company said.

Folate – typically found in leafy vegetables, sprouts, fruits, yeast and dairy products – is unstable and susceptible to oxidation.

Bioavailability can decrease 70 per cent in three days in leafy vegetables if they are stored at room temperature, increasing to 95 per cent if cooked in water.

“Irrespective of whether ingested food contains natural or synthetically-derived folates, these are metabolized to 5-methyltetrahydrofolate, which is considered the biologically active form of the B-vitamin folic acid,”​ Carboni said.

Deficit of folate represents one of the most common nutritional deficiencies and may occur when dietary intake is inadequate, when an increased need is not matched by an increased intake (particular physiological conditions as pregnancy, lactation, children growing), when altered absorption/excretion (or losses) than usual are present and when metabolism or drugs assumption interfere with the ability of the body to use folate.

Folate is most commonly linked with reducing the incidence of neural tube defects.

Another calcium alternative - calcium sulphate – has won Food and Agriculture Organization/World Health Organization Joint Expert Committee on Food Additives (JECFA) approval as a food additive.

It recommended a daily intake (RDI) of 2500mg that did not specify between various calcium forms.

A rat study found no difference in calcium bioavailability from different sources.
Human studies showed calcium sulphate bioavailability from mineral waters is comparable to milk and that sulphate anion does not affect the urinary excretion of calcium.

Related news

Show more

Related products

show more

Vitamin K2 Success Stories: NattoPharma

Vitamin K2 Success Stories: NattoPharma

NattoPharma USA, Inc. | 23-Sep-2019 | Case Study

Partnership means companies are bound to the process – from formulation and testing to marketing and meeting demand. That is what companies selecting MenaQ7®...

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals | 01-Sep-2019 | Application Note

The industry has shown improvement in its transparency in the past 5 years. Per the regulations, a Brand Owner is 100% responsible for the quality of...

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 01-Sep-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars